Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2016 · 10-Q
Revenue$31.85M$31.85M±0.0% vs Q3 2015 Net Income-$28.95M-$28.95MN/M vs Q3 2015 EPS Diluted-$0.23-$0.23N/M vs Q3 2015 Gross Profit$4,197,000±0.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$8,748,000N/M Free Cash Flowderived-$9,172,000N/M Margins · derivedGross margin13.2%±0.0 pt vs Q3 2015
Operating margin-71.4%+1.6 pt vs Q3 2015
Net margin-90.9%±0.0 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 7, 2016 · 38 d after period end